We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease.
- Authors
He, Dewei; Liu, Yanting; Li, Jie; Wang, Hefei; Ye, Bojian; He, Yuan; Li, Zhe; Gao, Xiyu; Fu, Shoupeng; Liu, Dianfeng
- Abstract
Parkinson's disease (PD) is a neurodegenerative disease in which neuronal apoptosis and associated inflammation are involved in its pathogenesis. However, there is still no specific treatment that can stop PD progression. Isoalantolactone (IAL) plays a role in many inflammation-related diseases. However, its effect and mechanism in PD remain unclear. In this study, results showed that IAL administration ameliorated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced PD-related pathological impairment and decreased motor activity in mice. Results from in vitro mechanistic studies showed that IAL regulated apoptosis-related proteins by activating the AKT/Nrf2 pathway, thereby suppressing the apoptosis of SN4741 cells induced by N-methyl-4-phenylpyridinium Iodide (MPP+). On the other hand, IAL inhibited LPS-induced release of pro-inflammatory mediators in BV2 cells by activating the AKT/Nrf2/HO-1 pathway and inhibiting the NF-κB pathway. In addition, IAL protected SN4741 from microglial activation-mediated neurotoxicity. Taken together, these results highlight the beneficial role of IAL as a novel therapy and potential PD drug due to its pharmacological profile.
- Subjects
PARKINSON'S disease; PATHOLOGY; APOPTOSIS; NEURODEGENERATION; MICROGLIA
- Publication
Cells (2073-4409), 2022, Vol 11, Issue 18, pN.PAG
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells11182927